Cargando…

Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model

Medullary thyroid carcinoma (MTC) is a well-known neuroendocrine carcinoma, derived from C cells of the thyroid gland. Additionally, MTC is an uncommon aggressive carcinoma that metastasizes to lymph nodes, bones, lungs and liver. For MTC, the 10-year general survival ratio of patients with localize...

Descripción completa

Detalles Bibliográficos
Autores principales: Yun, Hyeok-Jun, Lim, Jin-Hong, Kim, Sang-Yong, Kim, Seok-Mo, Park, Ki-Cheong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405678/
https://www.ncbi.nlm.nih.gov/pubmed/36009450
http://dx.doi.org/10.3390/biomedicines10081901
_version_ 1784773936725098496
author Yun, Hyeok-Jun
Lim, Jin-Hong
Kim, Sang-Yong
Kim, Seok-Mo
Park, Ki-Cheong
author_facet Yun, Hyeok-Jun
Lim, Jin-Hong
Kim, Sang-Yong
Kim, Seok-Mo
Park, Ki-Cheong
author_sort Yun, Hyeok-Jun
collection PubMed
description Medullary thyroid carcinoma (MTC) is a well-known neuroendocrine carcinoma, derived from C cells of the thyroid gland. Additionally, MTC is an uncommon aggressive carcinoma that metastasizes to lymph nodes, bones, lungs and liver. For MTC, the 10-year general survival ratio of patients with localized disease is about 95%, whereas that of patients with local phase disorder is around 75%. Only 20% of patients with distant metastasis to lung at diagnosis survive 10 years, which is notably lower than survival for well-differentiated thyroid carcinoma (WDTC). The management of MTC with distant metastasis to lung could be re-surgery or chemotherapy. In this research, we planned to assess the in vitro and in vivo combinational anticancer effect of a novel combination of low-dose cisplatin and sorafenib in patient-derived MTC. The patient-derived MTC cell lines YUMC-M1, M2, and M3 were isolated and treated with a combination of cisplatin and sorafenib or either agent alone. Cisplatin and sorafenib acted in combination to forward tumor restraint compared with each agent administered alone at a low dose. Therefore, a combination of cisplatin and sorafenib could be a new therapeutic approach for MTC.
format Online
Article
Text
id pubmed-9405678
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94056782022-08-26 Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model Yun, Hyeok-Jun Lim, Jin-Hong Kim, Sang-Yong Kim, Seok-Mo Park, Ki-Cheong Biomedicines Article Medullary thyroid carcinoma (MTC) is a well-known neuroendocrine carcinoma, derived from C cells of the thyroid gland. Additionally, MTC is an uncommon aggressive carcinoma that metastasizes to lymph nodes, bones, lungs and liver. For MTC, the 10-year general survival ratio of patients with localized disease is about 95%, whereas that of patients with local phase disorder is around 75%. Only 20% of patients with distant metastasis to lung at diagnosis survive 10 years, which is notably lower than survival for well-differentiated thyroid carcinoma (WDTC). The management of MTC with distant metastasis to lung could be re-surgery or chemotherapy. In this research, we planned to assess the in vitro and in vivo combinational anticancer effect of a novel combination of low-dose cisplatin and sorafenib in patient-derived MTC. The patient-derived MTC cell lines YUMC-M1, M2, and M3 were isolated and treated with a combination of cisplatin and sorafenib or either agent alone. Cisplatin and sorafenib acted in combination to forward tumor restraint compared with each agent administered alone at a low dose. Therefore, a combination of cisplatin and sorafenib could be a new therapeutic approach for MTC. MDPI 2022-08-05 /pmc/articles/PMC9405678/ /pubmed/36009450 http://dx.doi.org/10.3390/biomedicines10081901 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yun, Hyeok-Jun
Lim, Jin-Hong
Kim, Sang-Yong
Kim, Seok-Mo
Park, Ki-Cheong
Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model
title Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model
title_full Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model
title_fullStr Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model
title_full_unstemmed Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model
title_short Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model
title_sort discovery of pharmaceutical composition for prevention and treatment in patient-derived metastatic medullary thyroid carcinoma model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405678/
https://www.ncbi.nlm.nih.gov/pubmed/36009450
http://dx.doi.org/10.3390/biomedicines10081901
work_keys_str_mv AT yunhyeokjun discoveryofpharmaceuticalcompositionforpreventionandtreatmentinpatientderivedmetastaticmedullarythyroidcarcinomamodel
AT limjinhong discoveryofpharmaceuticalcompositionforpreventionandtreatmentinpatientderivedmetastaticmedullarythyroidcarcinomamodel
AT kimsangyong discoveryofpharmaceuticalcompositionforpreventionandtreatmentinpatientderivedmetastaticmedullarythyroidcarcinomamodel
AT kimseokmo discoveryofpharmaceuticalcompositionforpreventionandtreatmentinpatientderivedmetastaticmedullarythyroidcarcinomamodel
AT parkkicheong discoveryofpharmaceuticalcompositionforpreventionandtreatmentinpatientderivedmetastaticmedullarythyroidcarcinomamodel